NCT03665610View on ClinicalTrials.gov

Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites

CompletedOBSERVATIONAL
Enrollment

212

Participants

Timeline

Start Date

September 10, 2018

Primary Completion Date

January 10, 2019

Study Completion Date

January 10, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

ozanimod

ozanimod

Trial Locations (2)

78209

ICON Early Phase Services, LLC, San Antonio

78744

PPD Phase 1 Clinic, Austin

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY